T. Rowe Price Associates’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $40.5M | Buy |
2,895,265
+1,207,136
| +72% | +$16.9M | ﹤0.01% | 784 |
|
|
2025
Q1 | $22.8M | Buy |
1,688,129
+361,318
| +27% | +$4.87M | ﹤0.01% | 925 |
|
|
2024
Q4 | $25.4M | Buy |
1,326,811
+1,281,799
| +2,848% | +$24.6M | ﹤0.01% | 930 |
|
|
2024
Q3 | $1.03M | Buy |
45,012
+593
| +1% | +$13.5K | ﹤0.01% | 1959 |
|
|
2024
Q2 | $578K | Buy |
44,419
+13,050
| +42% | +$170K | ﹤0.01% | 2134 |
|
|
2024
Q1 | $550K | Buy |
31,369
+5,429
| +21% | +$95.2K | ﹤0.01% | 2170 |
|
|
2023
Q4 | $565K | Sell |
25,940
-585
| -2% | -$12.7K | ﹤0.01% | 2124 |
|
|
2023
Q3 | $407K | Buy |
26,525
+2,580
| +11% | +$39.6K | ﹤0.01% | 2208 |
|
|
2023
Q2 | $570K | Buy |
23,945
+1,286
| +6% | +$30.6K | ﹤0.01% | 2058 |
|
|
2023
Q1 | $577K | Sell |
22,659
-2,235
| -9% | -$56.9K | ﹤0.01% | 2044 |
|
|
2022
Q4 | $727K | Buy |
24,894
+7,340
| +42% | +$214K | ﹤0.01% | 1953 |
|
|
2022
Q3 | $361K | Buy |
+17,554
| New | +$361K | ﹤0.01% | 2292 |
|